# Single Dose Two-Way Crossover Fasted Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers

> **NCT00864968** · PHASE1 · COMPLETED · sponsor: **Actavis Inc.** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Nabumetone 750 mg tablets, single dose
- **DRUG:** Nabumetone 750 mg tablets, single dose

## Key facts

- **NCT ID:** NCT00864968
- **Lead sponsor:** Actavis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2010-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00864968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00864968, "Single Dose Two-Way Crossover Fasted Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00864968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*